D
Duquesne Family Office LLC
+ HoldingPURR
+9.98%
3M Return
$9.800
+0.341 (+3.48%)At close
Loading chart…
- High
- 9.845
- Open
- 9.000
- VWAP
- 9.53
- Volume
- 13.26M
- Mkt Cap
- —
- Low
- 8.954
- Amount
- 126.40M
- EV/EBITDA, TTM
- 0.36
Hyperliquid Strategies Inc is a digital asset treasury company. The Company is focused on accumulating HYPE, the native token of Hyperliquid, a high-performance blockchain custom-built to house all of finance. The Company’s subsidiary is Sonnet BioTherapeutics Holdings, Inc., which is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bifunctional action.
AI analysis of Hyperliquid Strategies Inc (PURR)
BuyHyperliquid Strategies Inc (PURR) is a good buy right now due to its significant growth potential and strong market position. The current price is $11.11, and analysts have set a price target of $18, which represents a potential upside of 63%. Additionally, the company has shown impressive revenue growth, with Q4 2026 revenue reaching $6.33 million, and a gross margin of 100% in the last three quarters, indicating strong profitability. However, the main risk is the ongoing investigation into insider trading, which could impact market sentiment and investor confidence.
Valuation Metrics
The current forward P/E ratio for Hyperliquid Strategies Inc (PURR) is 14.20, compared to its 5-year average forward P/E of 14.20.
Whales holding PURR
Events Timeline
News
7.009-29CNBCHouse Expands Investigation into Insider Trading in Prediction Markets
6.009-15CNBCLatest Rating Updates from Wall Street
8.509-15stocktwitsCompass Point Initiates Coverage on Hyperliquid Strategies with Buy Rating
2.009-07NASDAQ.COMHyperliquid Strategies Surges 94% in August 2026
8.509-07FoolHyperliquid Strategies Shares Surge 94% in August 2026
PURR FAQ — answered by Alphio AI
Hyperliquid Strategies Inc is a digital asset treasury company. The Company is focused on accumulating HYPE, the native token of Hyperliquid, a high-performance blockchain custom-built to house all of finance. The Company’s subsidiary is Sonnet BioTherapeutics Holdings, Inc., which is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bifunctional action. It operates in the Technology sector.
Hyperliquid Strategies Inc (PURR) is a good buy right now due to its significant growth potential and strong market position. The current price is $11.11, and analysts have set a price target of $18, which represents a potential upside of 63%. Additionally, the company has shown impressive revenue growth, with Q4 2026 revenue reaching $6.33 million, and a gross margin of 100% in the last three quarters, indicating strong profitability. However, the main risk is the ongoing investigation into insider trading, which could impact market sentiment and investor confidence.
Community
More ↗No posts yet
Sign up or log in to join the discussionThis page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.